SkyView Investment Advisors’s TriSalus Life Sciences TLSI Stock Holding History

SkyView Investment Advisors’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-150,000	Closed	-$1.57M	–	750
2023 Q2	$1.57M	Hold	150,000	–	–	0.39%	74
2023 Q1	$1.54M	Hold	150,000	–	–	0.36%	68
2022 Q4	$1.5M	Hold	150,000	–	–	0.46%	58
2022 Q3	$1.49M	Hold	150,000	–	–	0.44%	64
2022 Q2	$1.48M	Hold	150,000	–	–	0.39%	73
2022 Q1	$1.47M	Buy	+150,000	New	+$1.48M	0.35%	79

Other funds holding TLSI

CWM

Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return

Anson Capital Tyrone, Georgia $154M AUM 17.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GWSG

GPS Wealth Strategies Group Centennial, Colorado $117M AUM 24.22% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

SkyView Investment Advisors's TLSI Position: Q3 2023 in Review

SkyView Investment Advisors sold out of TriSalus Life Sciences (TLSI) in Q3 2023, closing a stake of 150,000 shares — an estimated $1.57M sold.

SkyView Investment Advisors first reported a position in TLSI in Q1 2022 and held it in 6 quarters. The position peaked at $1.57M in Q2 2023. 9 funds tracked by Wall St. Rank hold TLSI as of Q3 2023.

SkyView Investment Advisors reported no remaining TriSalus Life Sciences position as of Q3 2023 after selling out during the quarter.
SkyView Investment Advisors sold 150,000 TriSalus Life Sciences shares in Q3 2023, an estimated $1.57M.
SkyView Investment Advisors first reported a position in TriSalus Life Sciences in Q1 2022 and held it in 6 quarters.
SkyView Investment Advisors's TriSalus Life Sciences position peaked at $1.57M in Q2 2023.
9 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q3 2023.

Based on SkyView Investment Advisors's 13F filing for Q3 2023, filed 17 Nov 2023.